Q-omics provides the consensus-scored METAP2 profile across patient tissues and cancer cell-line models. METAP2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, METAP2 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, METAP2 protein abundance shows 29,031 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, HNSC, and GBM as cancer lineages where METAP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for METAP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes METAP2 survival associations across molecular data types. METAP2 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible METAP2 RNA expression–survival associations across cancer types. High METAP2 expression shows unfavorable associations in ACC, KIRP, HNSC and LIHC, but favorable associations in UCS and KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for METAP2 RNA expression.
This table summarizes METAP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for METAP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. METAP2 shows lower tumor expression in KICH and higher tumor expression in HNSC, LIHC, COAD, STAD and LUSC. The HNSC box plot shows higher METAP2 RNA expression in tumor versus normal tissue (log2 FC = +0.562, t-test p < 0.001).
This table shows molecular features associated with METAP2 in patient tissues and cancer cell lines. In patient samples, METAP2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, METAP2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Lymphoma.
